457 related articles for article (PubMed ID: 33682732)
1. The α-Synuclein Origin and Connectome Model (SOC Model) of Parkinson's Disease: Explaining Motor Asymmetry, Non-Motor Phenotypes, and Cognitive Decline.
Borghammer P
J Parkinsons Dis; 2021; 11(2):455-474. PubMed ID: 33682732
[TBL] [Abstract][Full Text] [Related]
2. Asymmetric Dopaminergic Dysfunction in Brain-First versus Body-First Parkinson's Disease Subtypes.
Knudsen K; Fedorova TD; Horsager J; Andersen KB; Skjærbæk C; Berg D; Schaeffer E; Brooks DJ; Pavese N; Van Den Berge N; Borghammer P
J Parkinsons Dis; 2021; 11(4):1677-1687. PubMed ID: 34334424
[TBL] [Abstract][Full Text] [Related]
3. The brain-first vs. body-first model of Parkinson's disease with comparison to alternative models.
Borghammer P
J Neural Transm (Vienna); 2023 Jun; 130(6):737-753. PubMed ID: 37062013
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of copper transporter 1 prevents α-synuclein pathology and alleviates nigrostriatal degeneration in AAV-based mouse model of Parkinson's disease.
Gou DH; Huang TT; Li W; Gao XD; Haikal C; Wang XH; Song DY; Liang X; Zhu L; Tang Y; Ding C; Li JY
Redox Biol; 2021 Jan; 38():101795. PubMed ID: 33232911
[TBL] [Abstract][Full Text] [Related]
5. Mutant α-Synuclein Overexpression Induces Stressless Pacemaking in Vagal Motoneurons at Risk in Parkinson's Disease.
Lasser-Katz E; Simchovitz A; Chiu WH; Oertel WH; Sharon R; Soreq H; Roeper J; Goldberg JA
J Neurosci; 2017 Jan; 37(1):47-57. PubMed ID: 28053029
[TBL] [Abstract][Full Text] [Related]
6. Chronic Mild Gut Inflammation Accelerates Brain Neuropathology and Motor Dysfunction in α-Synuclein Mutant Mice.
Kishimoto Y; Zhu W; Hosoda W; Sen JM; Mattson MP
Neuromolecular Med; 2019 Sep; 21(3):239-249. PubMed ID: 31079293
[TBL] [Abstract][Full Text] [Related]
7. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
8. Clinical and imaging evidence of brain-first and body-first Parkinson's disease.
Horsager J; Knudsen K; Sommerauer M
Neurobiol Dis; 2022 Mar; 164():105626. PubMed ID: 35031485
[TBL] [Abstract][Full Text] [Related]
9. Ageing promotes pathological alpha-synuclein propagation and autonomic dysfunction in wild-type rats.
Van Den Berge N; Ferreira N; Mikkelsen TW; Alstrup AKO; Tamgüney G; Karlsson P; Terkelsen AJ; Nyengaard JR; Jensen PH; Borghammer P
Brain; 2021 Jul; 144(6):1853-1868. PubMed ID: 33880502
[TBL] [Abstract][Full Text] [Related]
10. Alpha-synuclein pathology, microgliosis, and parvalbumin neuron loss in the amygdala associated with enhanced fear in the Thy1-aSyn model of Parkinson's disease.
Torres ERS; Stanojlovic M; Zelikowsky M; Bonsberger J; Hean S; Mulligan C; Baldauf L; Fleming S; Masliah E; Chesselet MF; Fanselow MS; Richter F
Neurobiol Dis; 2021 Oct; 158():105478. PubMed ID: 34390837
[TBL] [Abstract][Full Text] [Related]
11. Where and how alpha-synuclein pathology spreads in Parkinson's disease.
Wakabayashi K
Neuropathology; 2020 Oct; 40(5):415-425. PubMed ID: 32750743
[TBL] [Abstract][Full Text] [Related]
12. α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies.
Henderson MX; Trojanowski JQ; Lee VM
Neurosci Lett; 2019 Sep; 709():134316. PubMed ID: 31170426
[TBL] [Abstract][Full Text] [Related]
13. Brain-First versus Gut-First Parkinson's Disease: A Hypothesis.
Borghammer P; Van Den Berge N
J Parkinsons Dis; 2019; 9(s2):S281-S295. PubMed ID: 31498132
[TBL] [Abstract][Full Text] [Related]
14. Behavioral defects associated with amygdala and cortical dysfunction in mice with seeded α-synuclein inclusions.
Stoyka LE; Arrant AE; Thrasher DR; Russell DL; Freire J; Mahoney CL; Narayanan A; Dib AG; Standaert DG; Volpicelli-Daley LA
Neurobiol Dis; 2020 Feb; 134():104708. PubMed ID: 31837424
[TBL] [Abstract][Full Text] [Related]
15. Parkinson's disease and alpha-synucleinopathies: from arising pathways to therapeutic challenge.
Miraglia F; Betti L; Palego L; Giannaccini G
Cent Nerv Syst Agents Med Chem; 2015; 15(2):109-16. PubMed ID: 25896035
[TBL] [Abstract][Full Text] [Related]
16. Dopaminergic Dysfunction Is More Symmetric in Dementia with Lewy Bodies Compared to Parkinson's Disease.
Fedorova TD; Knudsen K; Horsager J; Hansen AK; Okkels N; Gottrup H; Vang K; Borghammer P
J Parkinsons Dis; 2023; 13(4):515-523. PubMed ID: 37212074
[TBL] [Abstract][Full Text] [Related]
17. Brain-first vs. body-first Parkinson's disease: An update on recent evidence.
Horsager J; Borghammer P
Parkinsonism Relat Disord; 2024 May; 122():106101. PubMed ID: 38519273
[TBL] [Abstract][Full Text] [Related]
18. Neuropathology of α-synuclein in Parkinson's disease.
Choong CJ; Mochizuki H
Neuropathology; 2022 Apr; 42(2):93-103. PubMed ID: 35362115
[TBL] [Abstract][Full Text] [Related]
19. Neural connectivity predicts spreading of alpha-synuclein pathology in fibril-injected mouse models: Involvement of retrograde and anterograde axonal propagation.
Mezias C; Rey N; Brundin P; Raj A
Neurobiol Dis; 2020 Feb; 134():104623. PubMed ID: 31628991
[TBL] [Abstract][Full Text] [Related]
20. What is the Evidence That Parkinson's Disease is a Prion Disorder, Which Originates in the Gut?
Kujawska M; Jodynis-Liebert J
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30424585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
